HC Wainwright Reaffirms “Buy” Rating for Apellis Pharmaceuticals (NASDAQ:APLS)

HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $92.00 price objective on the stock.

Several other brokerages also recently issued reports on APLS. Mizuho reiterated a neutral rating and set a $60.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. Robert W. Baird reiterated an outperform rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. UBS Group upped their target price on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a buy rating in a research report on Monday, March 4th. Raymond James upped their target price on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a strong-buy rating in a research report on Thursday, January 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an overweight rating in a research report on Wednesday, March 6th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $77.93.

Apellis Pharmaceuticals Stock Down 7.3 %

APLS opened at $48.03 on Monday. The firm’s 50-day simple moving average is $60.54 and its 200-day simple moving average is $57.04. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75. The firm has a market cap of $5.79 billion, a price-to-earnings ratio of -10.72 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting the consensus estimate of ($0.73). The business had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The firm’s quarterly revenue was up 545.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.50) EPS. Equities research analysts anticipate that Apellis Pharmaceuticals will post -1.33 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Pascal Deschatelets sold 69,107 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $58.66, for a total transaction of $234,640.00. Following the transaction, the chief financial officer now directly owns 93,338 shares of the company’s stock, valued at $5,475,207.08. The disclosure for this sale can be found here. In the last three months, insiders sold 406,651 shares of company stock valued at $25,130,257. 7.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Future Financial Wealth Managment LLC bought a new position in shares of Apellis Pharmaceuticals during the 1st quarter worth approximately $29,000. First Horizon Advisors Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 69.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after buying an additional 265 shares during the last quarter. Covestor Ltd boosted its holdings in shares of Apellis Pharmaceuticals by 564.2% in the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after buying an additional 677 shares during the last quarter. Stephens Consulting LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at approximately $38,000. Finally, US Bancorp DE boosted its holdings in shares of Apellis Pharmaceuticals by 391.2% in the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after buying an additional 884 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).